Русский
The effectiveness of the Speroton complex in the management of male factor infertility
DOI: https://dx.doi.org/10.18565/urology.2018.3.78-82
A.V. Kuz’menko, V.V. Kuz’menko, T.A. Gyaurgiev
Voronezh State Medical University n. a. N.N. Burdenko, Voronezh, Russiа
Introduction. One of the principles of contemporary management of male infertility is a correction of oxidative stress, replenishment of vitamins, microelements and low molecular weight peptides, and therefore multicomponent biologically active complexes, one of which is the Speroton, are widely used.
Aim. To investigate the effect of the Speroton complex on the functional sperm characteristics and fertility of men with pathozoospermia.
Materials and methods. We examined 60 men aged from 25 to 40 years old with male infertility against the background of various spermatogenesis disorders. Patients were randomized into two groups of 30 people each. A control group (CG) underwent general therapy. In the study group (SG) patients received a combination of general therapy and Speroton. The study participants were subsequently examined at four study visits. The parameters of the spermogram were assessed according to WHO criteria: sperm concentration, sperm motility, the total number of sperm with normal morphology, ejaculate volume and ejaculate liquefaction time, the level of fructose and zinc, and cases of pregnancy in the partner.
Results. The use of the Speroton complex resulted in a 10% increase in ejaculate volume, a 15.6% increase in sperm concentration, and a 32% reduction in liquefaction time. The proportion of progressively motile spermatozoa (grade A + B) showed a 2.6 fold increase due to activation of grade C spermatozoa. This, in our opinion, may be associated with a change in the ejaculate enzyme composition, which is indirectly confirmed by a 1.6 fold increase in the level of fructose and 15% increase in the amount of zinc in sperm biochemistry. The effectiveness of therapy in SG patients is also confirmed by 4 cases of spontaneous pregnancy, which occurred against a background of qualitative changes in sperm count.
Conclusion. The use of Speroton increases the sperm concentration and motility in patients with male factor infertility, and an increase in the number of spontaneous pregnancies in their partners.
Aim. To investigate the effect of the Speroton complex on the functional sperm characteristics and fertility of men with pathozoospermia.
Materials and methods. We examined 60 men aged from 25 to 40 years old with male infertility against the background of various spermatogenesis disorders. Patients were randomized into two groups of 30 people each. A control group (CG) underwent general therapy. In the study group (SG) patients received a combination of general therapy and Speroton. The study participants were subsequently examined at four study visits. The parameters of the spermogram were assessed according to WHO criteria: sperm concentration, sperm motility, the total number of sperm with normal morphology, ejaculate volume and ejaculate liquefaction time, the level of fructose and zinc, and cases of pregnancy in the partner.
Results. The use of the Speroton complex resulted in a 10% increase in ejaculate volume, a 15.6% increase in sperm concentration, and a 32% reduction in liquefaction time. The proportion of progressively motile spermatozoa (grade A + B) showed a 2.6 fold increase due to activation of grade C spermatozoa. This, in our opinion, may be associated with a change in the ejaculate enzyme composition, which is indirectly confirmed by a 1.6 fold increase in the level of fructose and 15% increase in the amount of zinc in sperm biochemistry. The effectiveness of therapy in SG patients is also confirmed by 4 cases of spontaneous pregnancy, which occurred against a background of qualitative changes in sperm count.
Conclusion. The use of Speroton increases the sperm concentration and motility in patients with male factor infertility, and an increase in the number of spontaneous pregnancies in their partners.
About the Autors
Corresponding author: A. V. Kuz’menko – Dr.Med.Sci., Associate Prof., Head of the Department of Urology, N.N. Burdenko VSMU, Voronezh, Russia; e-mail: Kuzmenkoav09@yandex.ru
Similar Articles
